Latest News & Features
Refine Search
Americas
With IP laws around the world subject to frequent and sometimes unpredictable changes, it can be difficult to keep abreast of everything you need to know. Richard Gough and Jane Woodhouse take a look. 1 May 2011
Americas
A recent study revealed that biotechnology companies or universities discovered 42 percent of all innovative drugs approved by the US Food and Drug Administration (FDA) between 1998 and 2007. 1 May 2011
Americas
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs. 1 May 2011
Americas
The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications. 1 May 2011
Europe
Recent European decisions have provided much to think about for practitioners concerned with DNA sequences. Caroline Pallard and Bart Swinkels investigate. 1 May 2011
Americas
Practitioners can take heart from recent developments in the Brazilian courts, say Otto Licks and Anderson Nascimento. 1 May 2011
Big Pharma
First instance courts in France have adopted controversial interpretations of an important Enlarged Board of Appeal decision, says Stéphane Agasse. 1 May 2011
Asia
It has taken a long time for India to develop a productive environment for biotechnology. But recent developments look to have put it on the right track. Archana Shanker explains. 1 May 2011
Americas
Homologation (recognition of equivalence) is a useful tool for simplifying administrative processes that are repeated in different countries. Nevertheless, it is not an end in itself. 1 May 2011
Big Pharma
There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions. 1 May 2011